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Systemic sclerosis (SSc) is a serious multiorgan disease, characterized by progressive fibrosis, 
vasculopathy and distinct serum auto antibodies (1, 2). Patients with SSc have an increased 
mortality risk and reduced quality of life (3-5). Interstitial lung disease (ILD) is a common 
manifestation in SSc and the leading cause of morbidity and mortality in the SSc population 
(3, 6). Classification of SSc was done with the 1980 American College of Rheumatology 
(ACR) classification criteria until 2013, when EULAR and ACR launched unified new 
classification criteria for SSc (7, 8).
The aim of the study was to estimate the prevalence of SSc in Norway, investigate survival 
and causes of deaths and to study fibrosis progression and lung function by serial assessments 
of high resolution computed tomography (HRCT) and concurrent pulmonary function tests 
(PFT). Additionally, we wanted to confirm the true value of the 2013 ACR/EULAR 
classification criteria for SSc. 
We found a prevalence of SSc in Norway of 9.9/100 000, a value comparable to other 
Northern European countries, supporting the notion of a north-south gradient of SSc in 
Europe with the lowest prevalence in Northern Europe. Our data show that mortality in SSc is 
still increased compared to the background population and the major causes of death are 
pulmonary hypertension (PH) and ILD. When studying lung fibrosis and lung function in 
serial assessments, we demonstrate that a normal baseline HRCT was highly predictive 
against later fibrosis development, and that HRCT findings at baseline predicted fibrosis 
progression rates and the deterioration rates of pulmonary function. Male gender, SSc 
subtype, antibodies, baseline fibrosis and baseline lung function were main risk factors for 
fibrosis development and progression. The 2013 ACR/EULAR SSc criteria performed 
remarkably well in our cohort and the sensitivity was significantly better than the ACR1980 
criteria using the combination of the ACR 1980 criteria and/or the Leroy & Medsger criteria 
as the “gold standard” for SSc. 
Our results reinforce the view that SSc is a rare but serious disease with increased morbidity 
and mortality and that pulmonary disease is a devastating complication. Our data support the 
notion that the 2013 ACR/EULAR criteria are a major step forward and that their application 
should improve the quality of clinical and epidemiological SSc research in the years to come. 
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1. Background
1.1 General introduction 
Systemic sclerosis is a rare, chronic connective tissue disease that affects the skin and internal 
organs, causes substantial morbidity and is associated with increased mortality (9, 10). The 
disease is characterized by micro vascular damage (vasculopathy) that leads to vessel 
obliteration, by fibroblast dysfunction with excessive collagen production, and by 
dysregulation of the immune system associated with the presence of specific autoantibodies, 
including anti-centromere antibody (ACA), anti-topoisomerase antibody (ATA) and anti-
polymerase III antibody (ARA) (1, 2, 11-16). The etiology remains uncertain, but seems to be 
multifactorial. Both environmental and genetic factors have been suggested as potential risk 
factors for SSc (17-22).
The disease includes a heterogeneous group of patients with varying disease manifestations, 
and it is subdivided into limited (lSSc), limited cutaneous (lcSSc) and diffuse cutaneous 
(dSSc) SSc according to skin involvement (7, 23). Skleroderma sine sclerosis and overlap 
syndromes with other connective tissue diseases are also subtypes of SSc (24, 25). 
Case assignment of SSc for research purposes have mostly been done with the ACR 
classification criteria from 1980 (7). Alternative classification systems were, however, 
increasingly used, particularly the Medsger & LeRoy three-subset system (23). In 2013, 
EULAR and ACR launched unified new classification criteria for SSc (8). In a multicenter 
SSc validation cohort, these criteria proved more sensitive than the 1980 ACR criteria. The 
criteria were also more specific, in terms of differentiating SSc from scleroderma like 
diseases. However, confirmation of the performance of the 2013 criteria in consecutive, 
unselected SSc patients, and the ability of the criteria to discriminate between SSc and mixed 
connective tissue disease (MCTD) as the most important and frequent scleroderma-related 
disease was not done.
The clinical symptoms of SSc depend upon the subtype and distribution of organ involvement 
(26, 27). Most frequently patients suffer from Raynaud’s phenomenon (RP), gastrointestinal 
involvement (GI) and muscle and joint affection (11, 28). Digital ulcers (DU), ILD, PH and 
renal crisis (SRC) are also frequent manifestations (26, 29-31). Often there is a long delay 
from initial symptoms to detection and diagnosis conceivably due to insidious onset and 
symptom heterogeneity. SSc is in general progressive; however, progression rate varies 
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according to SSc subtype and the severity of organ manifestation at first presentation (1, 27). 
Although progressive lung disease with fibrosis development is the major determinant of 
morbidity and mortality in SSc, prospective data on fibrosis progression rate and risk factors 
for progressive disease are limited (32-35). There are, however, no prospective data assessing 
the functional impact of, and risk factors for, lung fibrosis development and progression in 
SSc (36, 37). 
Treatment of SSc is challenging and at present time there is no curative treatment. 
Therapeutic intervention should be initiated early, but unspecific symptoms often delay the 
onset of treatment. Data on key issues like fibrosis progression rate and risk factors for 
progressive disease are limited (26). This makes targeted treatment difficult, and until now 
there is still no promising anti fibrotic treatment for SSc available (38).  
1.2 Epidemiology
SSc is a rare disease and few population based cohort studies on SSc epidemiology in 
Caucasians exist, but available data suggest that SSc usually develops in the age group 40 to 
50, with different peak incidences for gender and race (39-41). There is a female excess in 
SSc in all population studies with ratios between 3:1 and 6:1 (40). The reason for this female 
predominance is not well understood.  
Previous studies on SSc epidemiology have yielded annual incidence data varying between 
0.6 and 19/100.000 (39, 40, 42-45). Moreover, in several studies increasing incidence rates 
have been reported over the last decades (42, 43, 45). 
Prevalence rates have been reported ranging from 5/100.000 to 30/100.000 (39, 40, 42, 44, 
45). The prevalence estimates from the US and Australia appear to be higher than for Japan 
and Europe (39-41, 45, 46). The available data also indicate that the prevalence of SSc in the 
south of Europe may be higher than in the north, with prevalence rates of 15.8/100.000 
around Paris, France, 15.6/100.000 in Southern Croatia, 15.4/100.000 in Northwest Greece 
and 27.7/100.000 in Northwest Spain, compared to 8.8/100.000 in Northwest England and 
7.1/100.000 in Iceland (47-51). Notably, a recent study from Southern Sweden found one of 
the highest prevalence figures (23.5/100.000) ever seen in Europe; arguing against the 
presence of a north-south European SSc gradient (52). 
Nonetheless, it is clear from these studies that there are regional variations in SSc 
epidemiology data. It is not known if these variations reflect true population differences 
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caused by differential exposures to environmental triggers and/or genetic factors. They might 
also reflect differences in completeness of case ascertainment in the different studies, 
geographic location or absence of classification criteria prior to 1980 and better physician and 
patient’s awareness of the disease (11). 
Of unknown causes, even higher prevalence rates have been observed in several geographical 
clusters and in the native Choctaw Indian population (53-56).
Summarizing, it has been difficult to conduct population-based studies revealing the true 
prevalence and incidence. The majority of previously published studies were carried out in 
rather small populations and were often based on single centre or county data (47-49, 51). 
Therefore, we wanted to utilize the inherent properties of the Norwegian health system (free 
access to health care, electronic patient databases, reliable population statistics and the unique 
Norwegian identity numbers with “no loss to follow up) and conduct a population based 
cohort study on the true prevalence of SSc in Norway. 
1.3 Survival 
The overall survival rates of SSc vary depending on the degree of skin severity and 
distribution of organ involvement. Nonetheless, SSc is clearly a disorder with increased 
mortality and SSc patients continue to carry one of the highest risks of mortality of all 
connective tissue diseases (57, 58).
The observed mortality rates differ considerably between studies. Reported standardized 
mortality ratios (SMR) range from 1.5 to 7.2 (5, 50, 59-62) and the 5- and 10-year cumulative 
survival estimates range from 80 to 90% and 60% to 85%, respectively (4, 62-65).
Moreover, the frequency of deaths caused by SSc itself varies from 30% to 80% (3, 39, 57, 
62, 66-68). Very nicely demonstrated by Steen et al. in the Pittsburgh database, causes of 
death have changed over the past decades (3). Renal crisis was earlier the predominant cause 
of death, while in the last decade, pulmonary diseases were found to be the most frequent 
cause of death (3).
Factors previously associated with increased mortality have included male gender, older age 
at disease onset, dcSSc subtype and the presence of serum ATA as well as cardiovascular, 
pulmonary and renal disease involvement (4, 6, 29, 57, 69-75). 
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Since most of the previous mortality studies in SSc were conducted in single centres with 
selected cohorts, the large variations may, at least partly, be explained by selection bias. 
Therefore, we again wanted to use the advantages of the Norwegian health care system and 
conduct survival analyses in our population based SSc cohort for unbiased and complete data. 
1.4 Classification criteria 
Case assignment of SSc for research purposes were until 2013 mostly done with the 1980 
ACR classification criteria  (7). When these criteria for SSc were designed, the intention was 
“to be specific rather than sensitive to minimize false positive diagnoses”. Since these criteria, 
by definition, were not applicable to the full spectre of SSc, alternative classification systems, 
among others, LeRoy & Medzger’s modified criteria for early SSc were developed in 2001 
(23, 25, 76). Interpretation of earlier epidemiology studies was therefore hampered by the 
inconsistent use of classification criteria and subset definitions (76-78). Another challenge 
was that SSc is a heterogeneous disease where the phenotype depends upon the disease 
subtype and the distribution of organ involvement. In the early disease phase, the symptoms 
can be mild and subtle, and delineation against other connective tissue diseases (CTD), 
particularly MCTD might be difficult (11, 79, 80). 
Very recently, EULAR and ACR launched unified new classification criteria for SSc (8, 81-
83). It is evident from the joint ACR/EULAR publication that the 2013 criteria are a 
significant step forward, however, to confirm their true value, we wanted to evaluate the 
performance of the 2013 criteria in our consecutive, unselected SSc cohort, and assess the 
ability of the criteria to discriminate between SSc and MCTD as the most important and 
frequent scleroderma-related disease.  
1.5 Pathogenesis 
The pathological process involves three distinct features; micro vascular damage 
(vasculopathy) that leads to vessel obliteration, fibroblast dysfunction with excessive collagen 
production, and dysregulation of the immune system resulting, among other things, in 
disease-specific serum autoantibodies, most often ATA and ACA antibodies (17, 79). Both 
environmental and genetic factors have been suggested as potential risk factors for SSc (18-
20). Several possible environmental factors associated with SSc development, such as silica 
and solvents have been discussed (84, 85). Scleroderma-like syndromes have been described 
after exposure to different factors; including exposures with contaminated rapeseed oil in 
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1981 in Spain, exposure with vinyl chloride in the mid 60`s and development of nephrogenic 
systemic fibrosis after administration of gadolinium contrast material for magnetic resonance 
imaging in the setting of renal compromise (86-88). Lately, gastrointestinal (gut) micro biota 
has been discussed as an interesting possible environmental factor for other diseases (89-91). 
There is growing evidence that the bacteria in the gastrointestinal tract (the gut micro biota) 
might influence the development of autoimmunity in rodent models (91). However, there are 
only few studies on microbiota and autoimmune diseases and only one on microbiota in the 
skin of SSc patients (89). Research will be needed to identify specific bacterial species and to 
ascertain whether there are possible causal association between the development of SSc and 
the Gut microbiom. 
1.6 Skin disease
The skin is almost always affected in SSc and characterized by excessive fibrosis 
development. Clinically, it is marked by loss of flexibility due to indurations of the skin. SSc 
subtypes are mostly classified by the extent of the skin involvement (92). In lcSSc the skin 
thickening does not extent proximal to the elbows and knees. Many of these patients have 
only involvement of the face and the fingers. In lcSSc development of telangiectasias and 
calcinosis cutis is often seen. In dcSSc the skin involvement extents over the knee and elbows 
and affects often the whole body except for the upper back. Sine scleroderma has no affection 
of the skin and lSSc is defined as early SSc with no skin affection yet (also called 
prescleroderma). The degree of skin involvement is quantified using the validated modified 
Rodnan Skin Score (mRSS) (93-95). 
1.7 Gastrointestinal manifestations 
After skin involvement, the GI tract is the second most commonly involved organ system in 
SSc with over 90% of patients being affected (96). It is a leading cause of morbidity and 
mortality and a major contributor to poor quality of life (6). It can affect any site in the GI 
tracts, from the mouth to the anus (97). Symptoms vary based on location on affection with a 
variable extent and severity. The pathogenesis is elusive, but there is evidence of prominent 
fibrosis and alterations of smooth muscle cells and nerve fibres (98). The liver is mainly 
spared as a primary target in SSc. However, increased frequency of chronic liver diseases 
have been reported, especially the coexistence of primary biliary fibrosis (PBC) (99-102). 
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PBC is reported in 2-2.5% of all SSc patients and SSc has been estimated to occur in 4-15% 
of patients with PBC (100, 103-105). 
1.8 Cardiovascular diseases 
Traditionally, SSc had been considered as a fibrotic disease but over the last decades 
vasculopathy was revealed as an important key stone of SSc’s pathogenesis. Vascular disease 
imply a high burden for SSc patients and can manifest in SSc patients as Raynauds 
phenomenon, digital ulcers, telangiectasias, renovascular complications (including renal 
crisis) and pulmonary arterial hypertension (28, 29, 106-108). Patients may additionally suffer 
from erectile dysfunction (ED) (109-111). Nailfold capillaroscopy is increasingly used for the 
detection and imaging of microvascular changes and represents a safe and readily available 
imaging tool (112-115). Capillaroscopy has also been incorporated in the 2013 classification 
criteria for SSc (8). 
Cardiac involvement is common in SSc and can affect any cardiac structure both in lcSSc and 
dcSSc patients (116-119). The pathogenesis involves vasospastic mechanisms. Symptoms 
vary based on location on affection. When cardiac involvement gets symptomatic the 
prognosis is poor. Therefore, screening for sub clinical cardiac disease is essential but 
unfortunately, optimal screening tools are unknown.
1.9 Pulmonary manifestations 
Pulmonary diseases in SSc are the leading causes of deaths in SSc. There are two types of 
lung diseases in SSc (ILD and PH) with different pathogenesis, clinical features, predictors 
and treatment. The identification and predictive values for the detection of PH including 
isolated pulmonary arterial hypertension (PAH) has not been addressed in this thesis (120-
123).
1.9.1 Interstitial lung disease 
ILD is a common manifestation in SSc and the leading cause of morbidity and mortality in the 
SSc population with 35% of all SSc related death directly attributable to pulmonary fibrosis 
(3, 6).  Previous published data have shown that major lung involvement in SSc occurs early 
in the disease course (26, 124). ILD`s clinical course is heterogeneous and pulmonary 
manifestations vary widely; from limited non-progressive lung involvement to major 
pulmonary inflammation and fibrosis progressing to respiratory failure and death (32, 33, 75, 
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125). ILD can appear in both lcSSc and dcSSc; data from the EULAR multicenter SSc 
database showed that 53% of the enrolled patients with dcSSc and 35% with lc SSc had ILD. 
Several risk factors have been detected to predict ILD in SSc (35, 75, 126-129). The presence 
of an abnormal forced vital capacity (FVC) early in the disease has been reported as one of 
the most important risk factors for end stage lung disease (26, 130, 131). It has also been 
discussed whether the autoantibody profile may be a more powerful predictor for organ 
involvement than the disease subtype (27).  
SSc-ILD has typically an insidious onset with subtle clinical symptoms that are often non-
specific and a challenge to patients and physicians (132). PFTs play an important role in 
staging and serial monitoring of ILD in SSc (131). ILD in SSc is mostly associated with a 
restrictive ventilator defect, but coexistence of pulmonary vascular disease or extra-
pulmonary restriction may make the interpretation difficult. Usually, spirometric volumes are 
the most readily available measures and are highly reproducible but have clear limitations. 
PFT abnormalities are not specific for ILD, and wide normal ranges make baseline values 
difficult to evaluate (unless pre-morbid values are available). Benchmarking PFT at baseline 
is, nonetheless, critical for predicting outcome in SSc-ILD. In fact, serial PFT data suggest 
that forced vital capacity (FVC) decline to 50-70% within five years predict end-stage ILD 
and mortality (26, 127). 
HRCT is the primary tool used to determine the extent of lung affection in systemic sclerosis 
in SSc-patients with abnormal PFTs and/or clinical ILD symptoms (34, 37, 133, 134). The 
advent of HRCT has greatly enhanced the detection of ILD, with HRCT changes seen in up to 
55-65% of SSc patients and up to 96% of those with abnormal pulmonary function tests (37). 
The high diagnostic sensitivity of HRCT allows the detection of ILD at an earlier stage than 
ordinary chest radiographs and adequate staging to when and who commence with treatment 
(30, 133). It identifies the type of lung parenchyma abnormalities involved and allows for 
quantitative assessment of individual ILD components (34, 133, 134). Notwithstanding, there 
is no gold standard for differentiating between irreversible and reversible HRCT 
abnormalities, but the accumulated evidence suggest that reticular pattern changes may be 
considered as equivalents to lung fibrosis, and therefore represent the irreversible end of the 
abnormality spectre. Ground glass abnormalities typically represent the reversible end of the 
spectre. They are not specific for a distinct pathology, but may represent inflammatory 
processes in the lung parenchyma.  
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The potential value of quantitative HRCT fibrosis measurements in SSc was recently 
highlighted by Goh et al. (30). By combining cross-sectional HRCT analyses with follow-up 
PFT and survival data, they constructed a readily available prognostic algorithm for SSc-ILD, 
including both PFTs and HRCT findings. ILD is divided into a limited disease, an 
intermediary disease and an extensive disease, defined by baseline fibrosis </>20% and a 
baseline FVC>/<70%. It was shown that extensive disease was associated with high risk for 
mortality, also validated by Moore and co-workers (30, 69) 
Nonetheless, there is a substantial deficiency of data on key issues like fibrosis progression 
rate and risk factors for progressive disease. Little has been published on the utility and 
predictive value of serial HRCT in SSc (133). To date, there are no data on pulmonary 
fibrosis progression combining detailed lung fibrosis progression analyses with lung function 
tests in large longitudinal and prospective cohorts (37, 135).
Therefore, we wanted to determine the lung fibrosis progression rate and to analyse predictors 
for favourable and unfavourable lung outcome in a large, prospective SSc cohort by 
investigating pair wise data combining serial HRCT, PFT and clinical investigations. 
1.9.2 Pulmonary hypertension 
PH is common in SSc and occurs in two forms; isolated PAH and PH secondary to ILD. PAH 
is a disease of the small pulmonary arteries, characterized by progressive increase in 
pulmonary vascular resistance, ultimately causing right heart failure and death. It is defined 
by mean pulmonary artery pressure (PAP) >25 mmHg at rest measured by right heart 
catheterising (RHC) (31, 136). PAH is typically seen in patients with longstanding lcSSc 
without significant ILD (136, 137). No population data on PAH prevalence exist, but referral 
centre data indicate that it occurs in 10-15% of the patients. PAH has a major impact on 
quality of life (138) and takes often a rapid and devastating course. 
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2. Aims of the study
General aim 
Estimate the frequency and mortality of SSc, assess the lung fibrosis progression rate and 
identify predictive value for fibrosis progression in SSc and perform the 2013 classification 
criteria in an unselected, population based SSc cohort.
Our specific aims were: 
1. Estimate incidence, prevalence and gender ratio of SSc in south east Norway and 
evaluate possible geographic differences compared to earlier investigated populations 
2. Estimate the mortality and the causes of death of SSc patients compared to an age- and 
sex- adjusted control group, representing the general population 
3. Assess the sensitivity of the 2013 ACR/EULAR classification criteria for SSc on 
defined subgroups of SSc and in MCTD as a scleroderma related disease 
4. Evaluate the predictive value of serial HRCT, assess lung fibrosis progression rate and 
risk factors for progressive lung disease in SSc using pair wise serial HRCT analyses 
and concurrent pulmonary function tests 
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3. Patients and Methods  
3.1 Patient cohorts 
The Norwegian health system has inherent properties that make it highly suitable for 
population based studies (free access to health care, electronic patient databases, reliable 
population statistics and the unique Norwegian identity numbers with “no loss to follow up).
Over the last years, we have taken advantage of this and established two observational 
population based cohorts. First, the prospective SSc cohort at Oslo University Hospital 
(OUH) (Norwegian Systemic Connective Tissue Disease and Vasculitis Registry [NOSVAR]) 
that has been the basis for the performance of the 2013 classification criteria and for the 
detailed, serial HRCT analyses and concurrent pulmonary function tests in SSc and is 
described below. Second, the Southeast Norway SSc cohort formed the basis for the analyses 
of the prevalence and mortality of SSc in Norway. 
3.1.1 The prospective OUH SSc cohort: 
Since 2008, all the hospital databases at OUH are regularly screened to identify new eligible 
patients (i.e. patients with International Classification of Diseases (ICD-10) diagnoses 
compatible with SSc; M34.0, M34.1, M34.2, M34.8 or M34.9), which has been used in all 
Norwegian hospitals since 1999. This systematic database monitoring (and accompanying 
chart review by at least two SSc experts) allows for early detection of suspect SSc cases. All 
patients with an ICD-10 diagnosis compatible with SSc are continuously registered in 
NOSVAR. Patients who do not fulfil any criteria (predominantly SSc sine scleroderma and 
pre-scleroderma) are followed-up at the OUH outpatient clinic.  
3.1.2 The south east Norway SSc cohort
We aimed to identify and enrol every SSc patient living in Norway between 01.01.1999 and 
31.12.2012 in this cohort. Through collaboration with all hospital-based rheumatologists in 
south east Norway, we established an unselected and large population based SSc cohort, 
which included every identifiable patient in south east Norway.  
Different acquisition routes were used to identify every Norwegian patient with an ICD-10 
SSc diagnosis code (i.e. M34, see below).
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3.1.3 The MCTD cohort
The MCTD cohort included 178 patients, 147 patients enrolled in the unselected Norwegian 
nationwide MCTD cohort from 2005-08 and 31 included from the prospective OUH cohort 
NOSVAR from 2008-13 by Gunnarsson et al. (139, 140). Inclusion criteria for the MCTD 
cohort were; (141) (1) age = 18 years at inclusion, (2) fulfilment of at least one of three 
MCTD criteria sets (Sharp, Alarcón-Segovia and/or Kasukawa, and (3) exclusion of other 
CTDs (142).
3.2 Case finding strategy for SSc patients in southeast Norway 
By January 2010 Norway’s population consisted of 4801055 inhabitants. The denominator 
study population consisted of every person registered in the Norwegian Central Register with 
a home address in one of the 10 counties in southeast Norway with a total population of 
2707012 (56% of the total Norwegian population). There are eight Departments of 
Rheumatology and one department of dermatology in these ten counties. 
Five different acquisition routes (see below) were used to identify all the patients in the study 
area between 01.01.1999 and 31.12.2009 who had been registered with a SSc diagnosis code 
(M34) according to the 10th revised version of the International Classification of Diseases 
(ICD-10), which has been used in all Norwegian hospitals since 1999. 
Patients with an ICD-10 diagnosis code consistent with SSc were identified by the following 
five, partly overlapping acquisition routes:
1. The prospective SSc cohort (NOSVAR) of the Department of Rheumatology, at 
OUH was interrogated.  
2. All the other seven Departments of Rheumatology in southeast Norway were asked 
to interrogate their hospital database.  
3. All the rheumatology consultants practicing within the study region were invited to 
provide details of any patients under their care whom they considered to have SSc.
4. The one rheumatology department for children in Norway (located at OUH) was 
asked to interrogate their database for juvenile SSc patients.
5. The Department of dermatology at the OUH was asked to interrogate their database 
for SSc patients not taken care of by the rheumatology department.  
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All the hospital records were reviewed to evaluate whether the patient fulfilled the 1980 ACR 
and/or the Medsger & LeRoy classification criteria (7, 23). Finally, the records of every 
patient who fulfilled the criteria were re-examined to exclude other connective tissue diseases. 
All data were recorded retrospectively. Patients with CTD other than SSc and patients with 
localized scleroderma or morphea were excluded. 
3.3 Inclusion criteria for the prospective OUH cohort 
The OUH cohort NOSVAR was initiated before the 2013 ACR/EULAR classification criteria 
for SSc were developed. Thus, SSc patients were until 2013 included if they satisfied the 
ACR classification criteria from 1980 and/or Medsger & Leroy’s criteria from 2001 (7, 23). 
The patients were categorized into three SSc subtypes: 1. lSSc; defined by RP plus SSc-type 
nailfold capillary pattern or SSc specific auto antibodies, 2. lcSSc with skin thickening distal 
to the elbow/knee and 3. dcSSc with skin thickening proximal to the elbow/knee. 
After 2013, all SSc patients were enrolled if they fulfilled the 2013 classification criteria for 
SSc (8). Briefly, the criteria are based on a scoring system where the first criterion alone, skin 
thickening of the fingers of both hands extending proximal to the metacarpophalangeal 
(MCP) joints, gives the 9 points needed to classify the patient as SSc. If the first criterion is 
not met, the patient can gain 9 points by seven other items (8). 
3.4 Prevalence and Survival analysis
3.4.1 Prevalence 
The point prevalence of SSc was calculated at December 31st 2009.  
3.4.2 Assessment of SMR and survival rates
Using the personal identification numbers, we were able to identify every death and all the 
reported causes of death in the SSc cohort between 01.01.1999 and 01.01.2010. The vital 
status at the end of the study was established by contacting the Norwegian Central Person 
Register and by chart review. To calculate the SMR Statistics Norway provided a control 
group from the general Norwegian background population. Altogether 15 random controls 
were selected for each individual SSc patient. The controls were matched with the SSc patient 
for gender, year of birth and living area. Additionally, all the 15 controls were alive on the 
date of patient’s disease onset. For calculation of the SMR in the follow up period we 
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excluded all controls dying during the period of diagnostic delay and reduced the number of 
controls per patient accordingly.
3.4.3 Causes of death
The causes of death were based on information from medical charts, death certificates and 
autopsy. When the information from the different sources was not consistent, we used data 
from the medical chart and not from the death certificate. On three death certificates, SSc was 
not mentioned as a contributing cause of death (cause of death unknown). Causes of death of 
the control group were given by Statistics Norway. The causes of death of SSc patients were 
classified as SSc-related mortality and mortality unrelated to SSc. SSc related deaths were 
defined as deaths related to progressive, active SSc or deaths caused by organ failures directly 
related to SSc affection. Deaths unrelated to SSc were of all other causes and divided into 
several subgroups. If there was no notification on the death certificate or in the patient chart, 
the cause of death was defined as “unknown”.
3.5 Clinical parameters 
Clinical parameters were recorded in a standardised form and included: patient’s age, gender, 
smoking history, RP, skin involvement, organ involvement (including pitting scars and 
teleangiectasias), nailfold capillaroscopy, SSc-related antibodies, onset of RP and non-RP and 
vital status (28). PH was defined by the European Society of Cardiology (ESC) criteria (i.e. 
mean PAP > 25 mm HG by right heart catheterisation at rest) (31). ILD was assessed by 
HRCT and PFTs. The presence of ILD was defined by findings of fibrosis on HRCT and a 
FVC <70 % of the expected value (30).
Disease onset was defined as the first non-RP symptom. The period of time from disease 
onset until study end at the time of death was defined as the disease duration.  
3.6 Pulmonary function test
All included SSc patients underwent at least two PFTs, one at baseline and one at follow up. 
PFTs were systematically performed within 1 months of corresponding HRCT examination, 
following standard protocols. Lung function tests included dynamic spirometry and gas 
diffusing capacity. Recorded spirometric variables were: FVC, forced expiratory volume in 1 
s (FEV1) and FEV1/FVC. Gas diffusing variables were the DLCO and DLCO divided by 
alveolar volume (DLCO/VA). Lung function values were expressed in absolute values and as 
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percentage of predicted. Reference values were those recommended by the European 
Respiratory Society (ERS) (143). 
3.7 Acquisition and review of HRCT images  
Low-dose thin-section CT images were obtained in the supine position during breath-holding 
and deep inspiration. 
The images were reviewed independently and in random order by one experienced chest 
radiologists and one rheumatologist with training in interpretation of HRCTs. The observers 
were blinded to lung function and the patient’s clinical condition. In case of differing 
interpretations, final conclusions were reached by consensus. Reticular pattern (fine 
intralobular fibrosis without evident cysts; microcystic; and macrocystic) and super-imposed 
ground-glass opacities were defined as equivalent to fibrosis (144).
The extent of involvement was evaluated independently for each thin-section image, and each 
image was assigned a score based on the percentage of lung parenchyma that showed 
evidence of fibrosis. Area measurements were done precisely by drawing a freehand region of 
interest (ROI) on the PACS screen.  The overall extent of fibrosis was scored, and related to 
the total volume of lung parenchyma. The relationship between the overall volume of fibrosis 
and total lung volume was evaluated for HRCT at baseline and at follow up. To assess the 
sequential changes over time for each patient, the % rate of abnormal HRCT findings were 
compared with % rates on the other HRCT scan.
Patients were stratified in four subgroups by the extent of fibrosis on HRCT at follow up with 
0% fibrosis at baseline and follow up (group 1), 1-20% fibrosis at baseline and follow up 
(Group 2), 1-20% at baseline and >20% fibrosis at follow up (Group 3) and >20% at baseline 
and follow up (Group 4) (30, 133). 
3.8 Statistics 
Statistical analyses were performed by SPSS version 16-21 and STATA version 13. Causes of 
death were analyzed using standard descriptive statistics. Kaplan-Meier survival curves and 
significance was tested with the log rank test. Items with significant effects on survival were 
entered into the Cox proportional hazards model. The SMR was calculated as the ratio 
between the observed rate of death in the SSc cohort and the observed rate of death in the 
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comparable age- and gender-matched control group from Statistics Norway, representing the 
Norwegian background population. 
The association between potential risk factors and outcome was quantified by odds ratio (OR) 
with its 95% confidence interval (CI). Further, all independent risk factors significantly 
associated with survival or outcome measures from the univariate analysis at a significance 
level of 20% were considered as candidates in the multivariate logistic regression analysis. A 
manual backward stepwise elimination procedure using a multivariate logistic regression 
model was performed to identify independent risk factors for survival and outcome measures. 
Multivariate analyses were preceded by estimation of correlation between risk factors. 
Demographics, clinical and lung characteristics were analyzed using standard descriptive 
statistics. Differences in clinical findings between patients were analysed using Pearson Chi-
square test for contingency tables for categorical variables and independent sample t-test for 
continuous variables. Descriptive statistics were applied to analyse the number of patients of 
both cohorts meeting the newly established classification criteria for SSc. Sensitivity and 
specificity were calculated with confidence limits by using 2x2 tables with chi-square test. 
3.9 Ethics 
This study was approved by the regional committee (REK) of health and medical research 
ethics south east Norway (regional komité for medisinsk og helsefaglig forskningsetikk Sør-
Øst (No.2009/1035)). 
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4. Results 
4.1 Paper I 
Using the acquisition routes described, we identified a total of 369 patients diagnosed with 
SSc according to the ICD-10 coding system. Chart review revealed that 52 patients were 
miscoded and suffered from connective tissue diseases other than SSc (145). Another five 
patients were excluded as they did not fulfil the inclusion criteria. Since every person living in 
Norway has a unique Norwegian identity number, no patients were registered twice. Thus, the 
total number of SSc patients in the study area who fulfilled the ACR classification criteria for 
SSc and/or the Medsger& LeRoy’s criteria was 312, including five patients with juvenile 
onset.
The mean age at onset of the first non-Raynaud SSc symptom was 46.6 yrs. (SD 14.5 yrs.) for 
women and 47.2 yrs. (SD 15.4 yrs.) for men. The patients with dcSSc were younger at disease 
onset than the other subgroups and had shorter disease duration than lcSSc patients, but 
somewhat longer than lSSc patients. The female to male ratio of SSc in the study area was 
3.8:1. Forty three SSc patients died during the study period. The total number of SSc patients 
living in the study area by December 31st 2009 was thus 269. Of these patients, 35, 183 and 
51 were classified as lSSc, lcSSc and dcSSc, respectively. The overall ratio of lSSc to dSSc 
was 4.6:1. The ratio of limited to diffuse disease in women and men was 5.1:1 and 3.3:1. 
Approximately 95 % of the patients included were Caucasians.   
The point prevalence of SSc, according to the Medsger&LeRoy and ACR criteria, in 
southeast Norway by December 31st 2009 was estimated to 9.9/100.000 (95% CI 8.8-11.2), 
4.2/100.000 (95% CI 3.2-5.4) for males and 15.6/100.000  (95% CI 13.6-17.8) for females. 
We observed a distinct geographical variation in the prevalence of MCTD in Norway. The 
prevalence of SSc in the different Norwegian counties varied between 5.2 and 14.4/100.000 
(95% CI 2.8-8.8 and 10.3-19.6). The point prevalence for SSc by the ACR criteria alone was 
7.2/100.000 (95% CI 6.3-8.3).
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4.2 Paper II 
The total study cohort consisted of 95% Caucasians and included 312 patients fulfilling the 
ACR classification criteria for SSc and/or the Medsger& LeRoy’s criteria. 43/312 patients 
(14%) died during the study period (146). The deceased patient group consisted of 6 males 
with lcSSc and 9 males with dcSSc and 20 females with lcSSc and 8 with dcSSc. Male 
patients with dcSSc had a significantly higher mortality (43%) compared to females with 
dcSSc (17%) and to males and females with lcSSc (12% and 10%, respectively) (p-value 
0.03).
Chart review showed a higher frequency of ILD, PH associated with ILD (PH-ILD) and PAH 
in the 43 patients who died than in the surviving patients. Odds Ratio analyses identified ILD 
and PH (PAH and PH-ILD) as factors associated with mortality. Male gender and dcSSc 
subtype were also factors associated with a poor prognosis, whereas ACA was negatively 
associated with mortality. Multivariate logistic regression analysis showed that PAH 
(OR=8.0, 95% CI: 3.4-18.8) followed by ILD (OR=3.1, 95% CI: 1.5-6.6) were the strongest 
predictors for mortality. 
The overall SMR of the observation period was 2.03. The all-cause SMR was higher in males 
than in females, SMR for dcSSc was 5.33 compared to 1.62 for lcSSc.  
The Kaplan-Meier cumulative 5-year overall survival for SSc patients was 95%, and the 10-
year survival was estimated to 86%. The 5- and 10- year survival rates for lcSSc were 
estimated to 98 and 93%, and to 91% and 70% for dcSSc, respectively.
The death was attributable to SSc in 24 of the 43 deceased patients (56%). Sixteen of the 43 
deceased patients had death causes not attributable to the disease (37%) while three SSc 
patients died of sudden death of unknown causes (7%).
In total, 54% of the SSc attributable deaths were due to cardiopulmonary diseases, with 
pulmonary fibrosis (20%) and PAH/PH (20%) as the most frequent causes. All five patients 
dying from pulmonary fibrosis had extensive fibrosis according to the staging system by Goh
et al (30). All patients dying of PAH/PH had pre-capillary PH, no signs of post-capillary PH 
were noted. Another 25% of the patients died of SSc associated gastrointestinal causes while 
renal causes accounted for the death of five patients (20%). Three of the five patients with 
renal failure were diagnosed with SRC during their disease course (12.5%). They all died 
within three years after their SRC diagnosis. The 16 cases with non-SSc related causes of 
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death included malignancies (n=6), infections (n=2), coronary arterial disease (n=2), 
obstructive lung diseases (n=2), stroke (n=2) and bleeding anaemia (n=2).  
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4.3 Paper III
The OUH cohort included 425 consecutive SSc patients; 328 fulfilling the Leroy & Medsger 
criteria (23) (294 with lcSSc, 24 with prescleroderma and 10 with sine SSc) and 97 patients 
with dcSSc. Since prescleroderma and sine SSc, by definition, would not be captured by the 
1980 ACR criteria, only 391 patients were classifiable by these criteria. Hence, the frequency 
of patients meeting the ACR 1980 criteria was 75% (293/391). The mean age at disease onset 
was 48 years (SD 15.0) and the female to male ratio was 4:1. Altogether, 82 of the 
consecutive SSc patients had disease duration <1 year at study inclusion and in 239 the 
disease had lasted less than three years. Median disease duration of the whole SSc group was 
8 years, (range 0-44). ILD was identified in 174 patients (41% of the whole group) and 60 
(14%) had PH, verified by RHC.  
The 2013 EULAR/ACR classification criteria for SSc were met by 409 (96%) of the SSc 
patients, 97 of these (23%) were classified as SSc due to bilateral skin thickening proximal to 
the MCP joints. The remaining 312 patients reached 9 points or more by fulfilling other 
parameters defined by the criteria.  
The 16 SSc patients that did not meet the 2013 EULAR/ACR criteria had complete data on all 
the parameters defined by the criteria. They were classified as lcSSc (2 patients), pre-
scleroderma (6 patients) or sine SSc (8 patients).
The mean age of the MCTD patients at onset was 35 years (SD 15.7) and the female to male 
ratio was 4:1. Puffy fingers were present in 134/178 MCTD patients (75%), 54 (30%) had 
sclerodactyly, DU were recorded in 12 patients (7%) and four (2%) had SSc-related 
antibodies. ILD was identified in 44 patients (25%) and 5 (3%) had PH, as verified by RHC. 
The 2013 ACR/EULAR criteria for SSc were met by 18 patients (10%) in the MCTD cohort. 
All these 18 patients had RP, 17 had sclerodactyly, 4 had DU and 15 ILD, but none had PH.
The sensitivity for the new classification criteria was accounted to 96 % (95% CI 93.39, 
97.36) and the specificity to 90% (95% CI 84.85, 94.05). 
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4.4 Paper IV 
Of the 425 consecutive SSc patients enrolled in the prospective OUH SSc cohort, 305 had at 
least two pairs of lung HRCTs and corresponding PFTs available. The mean age at onset of 
first non-RP in these 305 patients was 48 years (SD 15.0). The mean time from non-RP onset 
until baseline HRCT was 4.2 years (SD 4.5) and the time lag between baseline HRCT and 
baseline PFTs was 0.01 years (SD1.5). Mean observation time between baseline and follow 
up HRCT was 3.1 years (SD 2.6) and the total disease duration, from non-RP onset to study 
end or death was 10.8 years (SD 7.8). Altogether, 67 patients (22%) died in the time period 
from the follow-up HRCT to the end of the study. 
At baseline, lung fibrosis was identified in 197/305 (65%) of the patients, while 108 patients 
had no signs of fibrosis. Strikingly, none of the 108 SSc patients without lung fibrosis at 
baseline had developed fibrosis on the follow-up HRCT, obtained mean 3.4 years later (group 
1). The 108 patients with no fibrosis were predominantly female (88%), had lcSSc (84%) and 
were ACA positive (70%) (group 1). In contrast, the 40 patients with >20% fibrosis at 
baseline were mostly dcSSc (55%), ATA positive (48%), and had a higher frequency of PH 
(28%) (group 4). Smoking habits did not differ across the groups. Of the 157 patients with 1-
20% fibrosis at baseline, 11 progressed to >20% fibrosis at follow up (group 3). These 11 
patients were characterized by significantly shorter mean disease duration at baseline (1.3 
years) than all the other groups.
At baseline HRCT, the mean fibrosis was 6.8% (SD 13.0). At the follow-up HRCT, fibrosis 
had progressed by 1.6% (SD 5.5). The mean fibrosis progression rate was highest (17.2%) in 
the 11 patients progressing from 1-20% fibrosis at baseline to >20% fibrosis at follow-up. The 
group with >20% fibrosis (n=40) at baseline and follow-up had higher fibrosis progression 
rate (2.7%) than the 146 patients with 1-20% fibrosis at baseline and follow-up (fibrosis 
progression rate 1.1%) (p-value <0.001).Only 19 patients had >10% fibrosis progression from 
baseline to follow-up. 
Mean baseline FVC % in the total SSc cohort was 92.7% (SD 20.9). The group with >20% 
baseline fibrosis had the lowest FVC % (69.9%). At follow-up, FVC % had declined by 4.8 % 
(SD 12.7) in the total cohort. FVC decline >10% was observed in 85/305 patients (28%), with 
highest frequency (46%) in the 11 patients with 1-20% fibrosis at baseline and >20% fibrosis 
at follow-up. Mean unadjusted DLCO % at baseline was 66.5% (SD 20.8) and the mean 
decline in DLCO % from baseline to follow-up was 8.2 % (SD 13.8). Patients with >20% 
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fibrosis at follow-up had lower mean DLCO % at baseline than the other groups, but there 
was no significant difference between the groups with respect to mean DLCO decline or 
frequency of DLCO decline >15%.  
Disease duration at baseline HRCT was <3 years in 58% of the patients (177/305), 4-10 years 
in 23% and >10 years in 19%. Percentage fibrosis at baseline did not differ between these 
three groups, but the group with <3 years disease duration had significantly higher fibrosis 
progression rate (2.2%) than the 4-10 years (0.8%) and >10 years (0.5%) groups. Moreover, 
13/19 patients with >10% fibrosis increase had <3 years disease duration. 
Univariate analyses showed significant associations between no lung fibrosis at follow-up and
anti-centromere antibodies (ACA), and between >20% fibrosis and male gender, dcSSc, anti-
topoisomerase antibodies (ATA) and PH. Both the primary outcomes were also associated 
with baseline values for FVC and DLCO. Univariate analyses of the secondary outcomes 
(FVC<70%, and FVC decline >10% from baseline to follow-up) were also performed. In the 
multivariate analyses, predictors for no lung fibrosis were ACA (OR 4.7) and baseline DLCO 
(OR 1.0), while >20% fibrosis was predicted by baseline values for fibrosis (OR 1.2) and 
FVC (OR 0.96) (Table 4). FVC<70% was predicted by baseline fibrosis (OR 1.0), FVC (OR 
0.9) and by ACA (OR 0.3). FVC decline >10% was also predicted by ACA (OR 0.4), and 
with the development of PH (OR 2.2). 
During the period from the follow-up HRCT to the end of study, 67 SSc patients (22%) had 
died. The deceased patients were significantly older at disease onset than the survivors, and 
had more often dcSSc and PH. Baseline values of FVC % and DLCO % were significantly 
associated with survival, and FVC % decline was higher among the deceased patients. The 
frequency of patients with >20% fibrosis at baseline was higher in deceased than surviving 
patients. Other lung fibrosis parameters were not significantly associated with survival.  
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5. General discussion 
5.1 What is the role of epidemiologic research? 
Although systemic sclerosis is one of the most enigmatic and challenging rheumatic diseases 
associated with a huge burden of morbidity and mortality surprisingly little has been known 
about causes, aetiology and pathophysiology. Fortunately, over the last decades research on 
SSc has increased tremendously and results are elucidating several aspects of this devastating 
disease, including clinical aspects, genetic and environmental factors and changes in the 
molecular level (17, 147-149). Disease management has also improved, clinicians and 
researchers dedicated to SSc are more aware of the heterogeneity of the disease, monitoring 
and possible treatment for different organ manifestations. Additionally, international 
collaboration has been established and has, among others, resulted in a large SSc cohort, the 
EUSTAR database (6, 27, 150). Many items, including data about SSc frequency, mortality 
and different organ affection have been published.
So why is further epidemiologic research interesting in an era marked by basic research 
progress and large international cohorts? Can epidemiologic researches from Norway, with its 
limited population add novel knowledge to the SSc society? Obviously, my answer is “yes, it 
is” for both questions. Firstly, although research of the last decades has lead to enormous 
advances in understanding of the disease we still do not know the cause and there no curative 
treatment exists. We really need future research into molecular mechanisms to improve our 
knowledge and find effective treatment. However, to know who to treat how, we need to 
classify and diagnose the right patients at the right time. In the era of evolving knowledge and 
awareness of SSc and new classification criteria, we really need updated and valid 
epidemiologic data about the true incidence, prevalence and mortality. For creating reliable 
epidemiological data of SSc, unselected and complete population based cohorts are the 
preferred basis for deriving those. Secondly, we want again elucidate that Norway is 
particularly suitable for epidemiologic studies because of the special Norwegian health care 
properties . Furthermore, Norway is a relatively small northern European country, its 
population is ethnically homogeneous, with less than 10% of the 4 800 000 inhabitants being 
of non-European ancestry and it has a climate and environmental exposures that differs from 
other northern European countries. All these items result in good prerequisite for reliable 
epidemiologic data and the possibility for novel knowledge.  
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In conclusion, we think that we have delivered novel and interesting data of the prevalence 
and the survival of SSc in a complete and unselected cohort causing the basis for more 
research. 
5.2 What does the lower prevalence in Norway tell us? 
We showed a lower prevalence (9.9/100.000) of SSc than in Southern Europe (15.4-
27.7/100.000), the US (27.6-44.3/100.000) and Australia (23.3/100.000) but comparable to 
other Northern European countries (7.1-8.8/100.000) (40). Until Andreasson et al published 
substantial higher prevalence data in southern Sweden (23.5/100.000) in July 2013 (52), we 
were convinced of a north south gradient of SSc in Europe. The health system of Sweden and 
Norway is comparable and both cohorts were complete, unselected and population based. So 
what does the lower prevalence in Norway compared to Sweden tell us? Our speculation that 
similar prevalence rates between the Northern European countries might be due to common 
genetic variants in the region has obviously to be reconsidered.
Could the awareness of SSc explain the differences? In our study, we observed variation in 
prevalence rates ranging from 5.2 to 14.4/100.000 in the ten Norwegian counties included in 
the study area. It appeared that the three counties with the lowest observed prevalence rates 
also had the lowest number of rheumatologists per capita, indicating that the observed 
differences could be due to missed SSc diagnoses due to lower awareness. Notably, the total 
population in these three counties only made up 20% of the total denominator population. 
Thus, any missed diagnoses would only have a minor impact on the overall observed SSc 
prevalence data. We believe that it is rather unlikely, that the awareness of rheumatologists in 
southeast Norway is significantly lower than in southern Sweden. However, the awareness of 
SSc in the primary health care system might be higher in southern Sweden and might explain, 
at least partly, the higher prevalence. 
As we know, the mechanisms behind SSc are not well understood, but involve genetic and 
environmental factors (151). The genetic contribution appears modest and, as mentioned, it is 
rather unlikely the only explanation for the different prevalence rates (17-19). Therefore, 
environmental factors come up as interesting aspects. Lately, there has been increasing focus 
on the microbiota in autoimmune diseases and there is growing evidence that the gut micro 
biota influence the development of autoimmunity (91). It has been supposed that people who 
are genetically predisposed to autoimmunity, harbour gut microbial communities that might 
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influence the onset and/or severity of a disease (90, 152, 153). Additionally, factors, like 
dietary changes exist that modulate the composition and function of the gut microbiom. Until 
now, there are no data on the gut microbiota in SSc, however, we know that there exist 
differences in diet and body mass index (BMI) varies worldwide. Therefore, might 
disturbance of the gut microbiota, as an environmental factor, explain the different prevalence 
rates world wide?  
In conclusion, we still do not know how to explain the lower prevalence of SSc in southeast 
Norway compared to southern Sweden, the US and Australia and further research is 
warranted. Especially, research will be needed to identify potential environmental factors.  
5.3 Has mortality changed over the last decades? 
We know that mortality is increased in SSc and that SSc patients continue to carry one of the 
highest risks of mortality of all systemic inflammatory diseases. However, few mortality data 
are derived from population based cohort studies and there has not been consistent use of 
classification criteria making it difficult to compare results from studies with different study 
designs and different cohorts. Earlier reported standardized mortality ratios (SMR) ranged 
from 1.5 to 7.2, with corresponding 5- and 10-year cumulative survival estimates of 80-95% 
and 60-85%, respectively. Both the observed SMR of 2.03 and the 5- and 10- year survival 
rates of 95% and 86% in the present study indicate that the mortality of SSc in southeast 
Norway is lower than reported in most other countries including other Scandinavian 
countries. In a study from Sweden, published in 1998, the 5- and 10- year survival rates were 
86% and 69% and the overall SMR 4.6. Data from Denmark, also from 1998, showed 5- and 
10- year survival rates of  81% and 71%, and an overall SMR estimated to 2.9 (4, 5). Why is 
the survival higher in Norway? We do believe that there are several possible explanations. 
Most obviously, the relatively low mortality mainly reflects that the South-East Norway 
cohort was population based and therefore included proportionally more patients with mild 
and early disease than cohorts from referral centres. This is also supported by the inclusion of 
SSc patients fulfilling the 1980 ACR criteria and/or the Medsger and LeRoy criteria for early 
SSc in the Norwegian cohort. In comparison, both the Swedish and the Danish cohort 
included only SSc patients fulfilling the 1980 ACR criteria and might have missed SSc 
patients with a milder and earlier disease course. In comparison with Northern American and 
southern European cohorts, our data might also reflect the rather homogenous population of 
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Caucasian descent, with a milder disease evolution and progression leads to increased 
survival of our cohort compared to cohorts with heterogeneous ethnicity (39, 154). 
Nonetheless, we do know that survival rates have been reported to have improved over the 
last decades (3). It has been suggested that this is due to earlier diagnosis and improvement in 
treatment of SSc patients, especially treatment of SRC. Renal crisis used to be the 
predominant cause of SSc-related death, but in the last decade pulmonary diseases have taken 
over. Our data of causes of deaths are in line with these reports. In the Southeast Norway 
cohort 56% of deaths were attributable to SSc with ILD (20%), PH (20%), and GI disease 
(25%) as the most frequent causes while SRC was the least cause of death and accounted only 
for 12.5% of all SSc related deaths. We do not have mortality data from different decades 
from our Norwegian cohort, however, comparison with the achieved data from Sweden and 
Denmark from the mid-90s might hypothetically reflect increased survival in the 
Scandinavian countries over the last two decades.  
In conclusion, although mortality data vary in some degree and despite that survival has 
improved in different reports over the last decades, our results reinforce the view that SSc is 
still a disease with increased mortality and that cardiopulmonary disease are now the leading 
causes of death.
5.4 Who do we classify with the new criteria? 
Classification criteria were initially proposed to enhance research by developing approaches 
for creating groups with similar patients. The main aims were to reach high sensitivity and 
specificity. In SSc the main goals were to include all SSc patients (sensitivity) and to exclude 
patients with scleroderma like disorders (specificity) (155). Historically, this has been 
challenging due to the heterogeneity of SSc and the wide range of clinical manifestations and 
the occurrence of different auto antibodies. The first classification criteria, the 1980 ACR 
criteria were not designed to identify patients with lcSSc, lSSc and sine scleroderma patients. 
Other criteria included these, like Medsger& Leroy’s criteria, but they were never validated. 
However, they included increasingly auto antibodies and nailfold capillary pattern. The 
varying use of different classification criteria were leading to inconsistency of research results 
as discussed earlier in this thesis.   
Very recently, EULAR and ACR launched unified new classification criteria for SSc (77, 78). 
In a multi-centre SSc validation cohort, these criteria proved more sensitive than the 1980 
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ACR criteria for the full spectrum of SSc (8). We showed in our consecutive, unselected SSc 
patients a high sensitivity of the new criteria. Only 4% of the cohort patients remained 
unclassifiable. These unclassifiable SSc cases had early disease. However, the 2013 
EULAR/ACR criteria did not discriminate completely between SSc and MCTD as the most 
important and frequent scleroderma-related disease. Ten percent of the MCTD patients met 
the 2013 SSc criteria, even in the absence of two criteria items (telangiectasias and nailfold 
capillaroscopy findings). We do believe that this high frequency mainly reflects the protean 
nature of MCTD and the potential evolution of MCTD into a more SSc-predominant 
phenotype over time. This answers the initial question: With the 2013 criteria for SSc, we will 
mainly classify SSc patients, however, we will still miss some SSc patients and might 
misclassify some patients with scleroderma like disorders. The clinical challenge of 
discerning especially MCTD from SSc will therefore, also in the future require detailed 
clinical work-up on a case to case basis and, in some cases, even longitudinal follow-up data. 
A future challenge will be the development of unified SSc subset classification criteria. We 
know that the clinical course, organ affection and survival often depend on the SSc subtype 
with dcSSc as the most severe subtype. Until now, the most widely accepted method is to 
divide patients clinically after skin involvement according to the distribution of skin 
thickening distal or proximal to the knee and/or elbow. However, measuring the skin 
thickening with the mRRS is dependent on the clinicians experience and regular application 
of the same clinician. Over the last decade, several different auto antibodies associated with lc 
and dcSSc have been detected, but not all are commercially available yet (1, 14, 29, 79). 
Fortunately, new SSc subset classification criteria combining typical clinical and serological 
profiles will be a useful tool for the enhanced early detection, patient treatment and 
monitoring in the future.
In conclusion, our data support the notion that the 2013 ACR/EULAR criteria are a major step 
forward and that their application should improve the quality of clinical and epidemiological 
SSc research in the years to come. We have still to be aware of scleroderma like disorders that 
can be misclassified as SSc. 
   
5.5 How do we follow our SSc patients with and without lung fibrosis?   
Interstitial lung disease is common in SSc but the clinical course is heterogeneous and 
severity varies widely; from limited non-progressive lung involvement to major pulmonary 
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inflammation and fibrosis progressing to respiratory failure and death. It is important to 
identify SSc patients with poor lung outcome early and to identify predictors for future 
fibrosis progression. HRCT and PFTs are the hallmarks in the detection of ILD in SSc and in 
the prediction of outcomes. Intuitively, it appears that lung HRCT has huge potential in SSc. 
Screening by HRCT early in the disease course would not only allow for early detection of 
ILD, but also exclude the presence of SSc-ILD at that stage. However, the value of (early) 
lung HRCT screening in SSc is not known. Notwithstanding, high awareness and routine 
monitoring are essential for early detection, but we are still lacking guidelines for monitoring 
SSc patients with and without lung fibrosis. How do we follow SSc patients without ILD? Do 
we need follow up HRCTs and/or PFTs on these? How do we monitor patients with 
diagnosed ILD? Do we need follow up HRCTs and PFTs on those? 
To answer these questions, we performed detailed, serial HRCT analyses of fibrosis 
progression in a prospective SSc cohort with comprehensive follow-up data on HRCTs, PFTs 
and clinical data. Our major findings were that 1. A baseline HRCT without fibrosis is highly 
predictive of a fibrosis free disease course. However, FVC declines mildly and DLCO is 
declining significantly in those patients. 2. Extensive lung fibrosis occurs very early in the 
course of SSc, progresses more rapidly than limited fibrosis and is associated with declining 
PFT values and DLCO and the development of PH. We also found that high proportion of 
lung fibrosis and deterioration of lung function during the disease course were predicted by 
male gender, dcSSc subtype, and presence of ATA, high extent of baseline fibrosis, low 
baseline FVC % and low DLCO% predicted. 
How do these results answer our initial questions? Firstly, our data suggest that patients with 
no fibrosis at baseline might not need any further HRCT scan but do benefit from lung 
function follow up and need further DLCO measurements based on mildly declining FVC and 
significant declining DLCO during the disease course. Secondly, patients with fibrosis at 
baseline need follow up investigations including HRCT and PFTs. It is very important to 
diagnose SSc patients early since lung fibrosis develops very early in the disease course. We 
are unfortunately not able to answer the question how often and how long patients need 
follow up investigations. Nonetheless, these are the first results combining serial lung imaging 
and lung function on SSc patients from a large and prospective and nearly unselected follow 
up cohort. We need clearly follow up studies to confirm those findings and to create 
guidelines for monitoring of SSc patients with and without fibrosis.
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In conclusion, we report the high predictive value of HRCT imaging and good long term 
outcome for patients with no fibrosis at baseline and that fibrosis occurs early, while 
progression of lung fibrosis can occur during the disease course. DLCO declined regardless of 
lung fibrosis. Male gender, dcSSc subtype, ATA, FVC % predicted <70 % and increased 
fibrosis at baseline are predictors for poor lung outcome and reduced survival.
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6. Main Conclusions          
1. The observed SSc point prevalence in southeast Norway of 9.9/100.000 is comparable 
to most previous data from other northern European countries. 
2. The low prevalence observed support the possibility of a north-south gradient of SSc 
in Europe. 
3. Mortality in SSc is high, particularly in the subset of patients with dcSSc and male 
gender.
4. The major causes of death were PH and lung fibrosis. 
5. Our data support the notion that the 2013 ACR/EULAR criteria are a major step 
forward and that their application should improve the quality of clinical and 
epidemiological SSc research in the years to come 
6. A normal baseline HRCT was highly predictive against future lung fibrosis
7. Extensive fibrosis occurred early in the disease course and was associated with high 
fibrosis progression rate and declining PFTs throughout the disease course.
8. Male gender, dcSSc subtype, ATA, FVC % predicted <70 % and increased fibrosis at 
baseline were predictors for poor lung outcome and reduced survival. 
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7. Clinical implications and future perspectives 
7.1 Clinical implication 
The main clinical implication of this study is that we need to diagnose SSc patients early and 
follow these with tight and planned controls. SSc is a rare but serious disease, development of 
ILD and PH is frequent and mortality due to these complications is high. Lung fibrosis 
develops early in the disease course and therefore diagnosis and tight controls are important, 
especially early in the disease course. Patients with no fibrosis at baseline might not need any 
follow up HRCT but will benefit from PFT controls since in the present study all SSc patients 
declined in DLCO even patients with no fibrosis. Declining DLCO can be associated with the 
development of PH and therefore all SSc patients need control of lung and cardiac function 
also later in the disease course.  
Our data support the notion that male SSc patients and dcSSc patients need particularly follow 
up due to higher likelihood of developing lung fibrosis and due to higher mortality. The 2013 
classification criteria might help to classify all SSc patients leading to possible earlier 
diagnosis, targeted treatment and facilitated monitoring. Still, we have to increase the 
awareness of SSc in the primary health care system even more in order to make early 
diagnosis possible.
7.2 Future perspectives
We have come further in SSc research but not far enough. We have neither found the cause of 
SSc nor very important genetic and/or environmental factors associated with SSc. However, it 
is rather unlikely that we will find only one, single cause or triggering factor in the future. 
Nonetheless, our goal has to be to increase the awareness of SSc and make early diagnosis of 
all eligible patients possible, treat as good as we can and increase patients quality of life and 
survival. Therefore, further broad research is required, from unselected and complete cohorts, 
from large international collaborations and on molecular levels.
Our research group wants to contribute with further research on our unique and unselected 
cohorts. The basic approach of our next project is to go from bedside to bench; meaning that 
our research will focus on the major clinical challenges in SSc and primarily aim for data that 
are of immediate benefit and relevance to the SSc society.
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In the first part, we assemble a unique, nationwide SSc cohort; the NORSE Cohort and 
describe how we will use this large, complete and unselected cohort for high-quality studies 
on the frequencies and impact of ILD, PAH, GI involvement and cancer. In addition, we will 
use our established prospective OUS SSc cohort, which is one of the largest worldwide, for 
inter-disciplinary studies on immunological and imaging biomarkers on PAH, ILD and GI 
involvement. Data from these “proof-of concept” studies will then be sought validated in the 
NORSE cohort. 
In collaboration with the University of California (UCLA), USA and the Jebsen Centre for 
Inflammation Research OUH, we will approach the hypothesis that gut microbiota play a role 
in SSc. If the preliminary analyses indicate associations between microbiota, GI involvement 
and other clinical parameters, these will be sought validated in the NORSE cohort. The 
project plan includes a one-year stay at UCLA to work on microbiota. 
We believe that the results of this future project should contribute important clinical data of 
immediate relevance for the patients and the physicians treating them. The more explorative 
part of the work will hopefully contribute to better understanding of the mechanisms behind 
PAH development and the influence of microbiota in SSc. 
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